Liver disease accounts for two million deaths annually and is responsible for 4% of all
deaths (1 out of every 25 deaths worldwide); approximately two-thirds of all liver-related …

Hepatology AASLD Publications Hepatology Liver Transplantation Hepatology Communications
Clinical Liver Disease Log in or Register Subscribe to journalSubscribe Get new issue …

Nonalcoholic fatty liver disease (NAFLD) is a leading cause of liver disease worldwide. The
estimated global incidence of NAFLD is 47 cases per 1,000 population and is higher among …

Non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common liver
disease globally and is currently estimated to affect 38% of the global population. Only a …

Background Pegozafermin is a long-acting glycopegylated (pegylated with the use of site-
specific glycosyltransferases) fibroblast growth factor 21 (FGF21) analogue in development …

Background & Aims The prevalence of non-alcoholic fatty liver disease (NAFLD) is
increasing. We aimed to estimate the pooled global NAFLD incidence. Methods We …

To date, non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease,
affecting up to 70% of patients with diabetes. Currently, there are no specific drugs available …

Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide.
Surveillance for HCC is critical for early detection and treatment, but fewer than one-quarter …

Background/Aims Due to increases in obesity and type 2 diabetes, the prevalence of
nonalcoholic fatty liver disease (NAFLD) has also been increasing. Current forecast models …

Alongside the liver, white adipose tissue (WAT) is critical in regulating systemic energy
homeostasis. Although each organ has its specialised functions, they must work …